Acumen Pharmaceuticals (ABOS) Cash from Operations (2020 - 2026)
Acumen Pharmaceuticals (ABOS) posted Cash from Operations of 24128000.0 for Q1 2026, down 26.35% sequentially from 19096000.0 in Q4 2025, and up 29.29% YoY from 18662363.15 in Q1 2025.
Acumen Pharmaceuticals (ABOS) Cash from Operations (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Cash from Operations for 7 years, with the latest figure at 24128000.0 in Q1 2026.
- Quarterly Cash from Operations rose 29.29% year-over-year to 24128000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 105545000.0 (down 2.99% YoY) and the FY2025 annual result came in at 115538000.0, down 34.01% from the prior year.
- Cash from Operations retreated to 24128000.0 in Q1 2026 per ABOS's latest filing, from 19096000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 6468000.0 in Q2 2022 and troughed at 34121000.0 in Q1 2025.
- A 5-year average of 17888117.65 and a median of 16545000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations slumped 250.17% in 2022, then rose 29.83% in 2025.
- Over 5 years, Cash from Operations stood at 11203000.0 in 2022, then rose by 25.79% to 8314000.0 in 2023, then plunged by 227.34% to 27215000.0 in 2024, then grew by 29.83% to 19096000.0 in 2025, then slipped by 26.35% to 24128000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 24128000.0, 19096000.0, and 30489000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Acumen Pharmaceuticals | 226.87 Mn | 226.87 Mn | - | -18.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.08 Mn |
| Jun 30, 2026 | -18.08 Mn |
| Mar 31, 2026 | -24.13 Mn |
| Mar 31, 2026 | -24.13 Mn |
| Dec 31, 2025 | -19.10 Mn |
| Dec 31, 2025 | -19.10 Mn |
| Sep 30, 2025 | -30.49 Mn |
| Sep 30, 2025 | -30.49 Mn |
| Jun 30, 2025 | -31.83 Mn |
| Jun 30, 2025 | -31.83 Mn |
| Mar 31, 2025 | -34.12 Mn |
| Mar 31, 2025 | -34.12 Mn |
| Dec 31, 2024 | -27.22 Mn |
| Dec 31, 2024 | -27.22 Mn |
| Sep 30, 2024 | -24.60 Mn |
| Sep 30, 2024 | -24.60 Mn |
| Jun 30, 2024 | -16.55 Mn |
| Jun 30, 2024 | -16.55 Mn |
| Mar 31, 2024 | -17.86 Mn |
| Mar 31, 2024 | -17.86 Mn |